This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
BioRad Laboratories (BIO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Bio-Rad Laboratories' (BIO) first-quarter 2023 results are likely to reflect an impressive performance across its Life Science segment, with a gradual reduction in backlogs and an improvement in the supply chain.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results likely to reflect rising volumes across all channels.
What's in Store for West Pharmaceutical (WST) in Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Robust performance from MyoSure and NovaSure along with increasing contributions from the company's laparoscopic portfolio are expected to have contributed to the Hologic's (HOLX) Q2 reveneus.
IDEXX Laboratories (IDXX) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) first-quarter 2023 results are expected to reflect an impressive performance in the CAG segment despite inflationary impacts.
Will Lower Managed Care Profits Hurt Centene's (CNC) Q1 Earnings?
by Zacks Equity Research
Centene's (CNC) first-quarter results are likely to reflect growth in premiums and lower costs.
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business is expected to have gained from improved U.S. patient traffic to physician offices, ultimate care sites and ambulatory surgical centers.
What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?
by Zacks Equity Research
Continued demand for the HemoSphere monitoring platform and Smart Recovery is likely to have contributed to the Edwards Lifesciences' (EW) Q1 growth.
Baxter (BAX) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics' (DGX) first-quarter 2023 results are likely to reflect an impressive performance in its non-COVID-19 base business amid inflationary pressure and labor challenges.
Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs, severe staffing shortages and supply issues.
Bio-Rad Laboratories (BIO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bio-Rad Laboratories (BIO) closed at $479.16 in the latest trading session, marking a -0.49% move from the prior day.
What's in Store for Boston Scientific (BSX) in Q1 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies in the first quarter.
What's in Store for Thermo Fisher (TMO) in Q1 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) is likely to have generated growth in the first quarter, driven by a favorable business mix and new launches.
HCA Healthcare (HCA) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter results are likely to reflect the impacts of increased inpatient and outpatient surgery cases.
Align Technology (ALGN) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) first-quarter 2023 results are likely to witness impressive performance across its operating segments amid macroeconomic pressure.
LabCorp (LH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ongoing sales rebound in the base business for both Diagnostics and Drug Development segments is likely to have benefited LabCorp (LH) in Q1.
QuidelOrtho (QDEL) Soars 5.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bio-Rad (BIO) Rises 6.5% Since Q4 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Bio-Rad's (BIO) strong global presence and stable solvency position.
Is BioRad Laboratories (BIO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bio-Rad Laboratories (BIO) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.
Elevance Health (ELV) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Elevance Health's (ELV) first-quarter results are likely to reflect higher premiums, commercial and government sales figures and total expenses.
Bio-Rad Laboratories (BIO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Bio-Rad Laboratories (BIO) closed the most recent trading day at $476.83, moving +1.02% from the previous trading session.
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
by Zacks Equity Research
Abbott Laboratories' (ABT) Established Pharmaceuticals Division (EPD) and Diabetes arm are boosting business in recent months.
Here's Why Investors Should Buy Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on robust growth in Life Science and Clinical Diagnostics arms.
UnitedHealth's (UNH) UnitedHealthcare Unit to Drive Q1 Earnings
by Zacks Equity Research
An increase in the total number of people served in commercial domestic business of UnitedHealth (UNH) is likely to have boosted its first-quarter performance.